| scholarly article | Q13442814 |
| P356 | DOI | 10.3899/JRHEUM.090832 |
| P698 | PubMed publication ID | 20231193 |
| P50 | author | Janet Pope | Q48742471 |
| P2093 | author name string | Tiffany Kwok | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | psoriatic arthritis | Q511097 |
| questionnaire | Q747810 | ||
| patient | Q181600 | ||
| P304 | page(s) | 1024-1028 | |
| P577 | publication date | 2010-03-15 | |
| P1433 | published in | The Journal of Rheumatology | Q7743623 |
| P1476 | title | Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales | |
| P478 | volume | 37 |
| Q47801491 | A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems |
| Q53090514 | A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. |
| Q55316418 | Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. |
| Q47588361 | Cross-cultural measurement equivalence of the EQ-5D-5L items for English-speaking Asians in Singapore |
| Q35613817 | Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment |
| Q49990438 | Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). |
| Q39066339 | Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis |
| Q46526564 | Estimating the minimum important change in the 15D scores |
| Q21245611 | Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS) |
| Q47148249 | Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. |
| Q38010363 | Measures of adult general functional status: SF-36 Physical Functioning Subscale (PF-10), Health Assessment Questionnaire (HAQ), Modified Health Assessment Questionnaire (MHAQ), Katz Index of Independence in activities of daily living, Functional In |
| Q38010362 | Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Chec |
| Q36069816 | Minimal important differences for fatigue patient reported outcome measures-a systematic review |
| Q28069592 | New targets in psoriatic arthritis |
| Q38071925 | Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. |
| Q82732857 | Osteoporosis in psoriatic arthritis: is there any? |
| Q38195568 | Patient involvement in outcome measures for psoriatic arthritis |
| Q38822369 | Patient-Reported Outcomes in Psoriatic Arthritis. |
| Q94322276 | Phosphodiesterase 4 inhibitors for psoriatic arthritis |
| Q34174214 | Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal study |
| Q26862017 | Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds En |
Search more.